Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.
2018
9036Background: Treatment options are limited in pts who progress on anti-PD-(L)1 therapy. HDAC inhibitors have the potential to modulate myeloid-derived suppressor cell (MDSC) function and may syn...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
14
Citations
NaN
KQI